Ventilator News and Research

RSS

Collaboration between nurses and physicians decreases rates of HAIs in critical care

Collaborative relationships between nurses and physicians decrease rates of healthcare-associated infections (HAIs) in critical care, according to an article in the April issue of Critical Care Nurse.

2 Apr 2015

NIH awards K23 grant to study effects of carbon dioxide levels after cardiac arrest

The NIH-National Heart Lung and Blood Institute has awarded Brian W. Roberts, MD, emergency medicine physician at Cooper University Health Care and Assistant Professor of Emergency Medicine at Cooper Medical School of Rowan University (CMSRU), a Mentored Patient-Oriented Career Development grant (K23) to study post-resuscitation partial pressure of arterial carbon dioxide and neurological outcome after cardiac arrest.

25 Mar 2015

Mallinckrodt enters into definitive agreement to acquire Ikaria

Mallinckrodt plc, a leading global specialty biopharmaceutical company, and Ikaria, Inc. a privately-held critical care company, announced today that they have entered into a definitive agreement under which a subsidiary of Mallinckrodt will acquire Ikaria, Inc. from a Madison Dearborn-led investor group in a transaction valued at approximately $2.3 billion.

5 Mar 2015

Blood tests in heart surgery patients can lead to anemia, blood transfusions

Laboratory testing among patients undergoing cardiac surgery can lead to excessive bloodletting, which can increase the risk of developing hospital-acquired anemia and the need for blood transfusion, according to an article in the March 2015 issue of The Annals of Thoracic Surgery.

2 Mar 2015

Lakeland Pharmacy seeks DAPA certification to pursue government procurement opportunities

Lakeland Pharmacy, a leading full-service pharmacy, pharmaceutical compounding shop, and medical device retailer, announced plans today to expand sales of their home respiratory equipment by applying for a Distribution and Pricing Agreement (DAPA) certification and actively pursuing government procurement opportunities.

17 Feb 2015

New Breathe NIOV System uses Bayer’s injection-molded Makrolon polycarbonate

Imagine not being able to climb the stairs without stopping to take a break, or getting winded trying to stand and do the dishes. Unfortunately these are common realities for individuals suffering from respiratory conditions. Ventilators can help reduce the work of breathing by unloading the ancillary respiratory muscles, but they are often bulky and heavy, creating additional limitations for users. The Breathe Non-Invasive Open Ventilation (NIOV) System technology is a better solution.

13 Feb 2015

Bayer materials withstand demanding conditions and meet requirements for innovative medical devices MD&M West

Increasingly, innovative medical applications place further importance on the success of the materials they use. When patients’ health, mobility and comfort are involved, reliability and durability are crucial. Bayer MaterialScience LLC steps up to the challenge offering original equipment manufacturers (OEMs) a wide range of material solutions for their medical application needs.

10 Feb 2015

Bayer offers wide range of material solutions for OEMs' medical application needs

Increasingly, innovative medical applications place further importance on the success of the materials they use. When patients' health, mobility and comfort are involved, reliability and durability are crucial. Bayer MaterialScience LLC steps up to the challenge offering original equipment manufacturers (OEMs) a wide range of material solutions for their medical application needs.

10 Feb 2015

UM SOM launches ‘Program in Lung Healing’ to develop treatments for acute respiratory failure

University of Maryland School of Medicine (UM SOM) Dean E. Albert Reece, MD, PhD, MBA, and Jeffrey A. Rivest, MS, President and Chief Executive Officer of University of Maryland Medical Center (UMMC), today announced the official launch of a new "Program in Lung Healing," that will further the School's position as a national leader in research, education and clinical innovation for acute ailments of the lung and respiratory system.

9 Feb 2015

Study: 20% of very-low-birth-weight babies born in California not referred for follow-up care

The tiniest babies need special follow-up care when they go home from the hospital after birth. But, of the thousands of very-low-birth-weight babies born in California during 2010 and 2011, 20 percent were not referred to the state's high-risk infant follow-up program, according to a new study by researchers at the Stanford University School of Medicine.

23 Jan 2015

Bathing critically ill patients with chlorhexidine wipes does not prevent ICU infections

Vanderbilt University Medical Center researchers have found that bathing critically ill patients with disposable chlorhexidine cloths did not decrease the incidence of health care-associated infections when compared to less expensive nonantimicrobial cloths, according to a study appearing online in JAMA this week.

22 Jan 2015

Experimental drug warrants clinical study for treatment of Ebola infection

A case report, published in The Lancet today, describes the successful treatment of Ebola using a new drug under clinical development for vascular leakage (FX06, a fibrin-derived peptide).

19 Dec 2014

Saint-Gobain Seals provides OmniSeal® spring-energized seals to OEM’s in the medical miniature motor market

Saint-Gobain Seals continues to provide their dynamic OmniSeal® spring-energized seals to OEM’s in the medical miniature motor market, which allows them to provide a well-balanced sealed motor and an added sense of security to their surgical tool OEM’s. The medical market has been growing quite rapidly with the need for more portable applications that are unobtrusive and efficient but still powerful.

8 Dec 2014

FDA Advisory Committee votes in favor of Actavis' ceftazidime-avibactam

Actavis plc today announced that the Anti-Infective Drugs Advisory Committee convened by the U.S. Food and Drug Administration has voted to recommend approval of Actavis' New Drug Application (NDA) for ceftazidime-avibactam, an investigational antibiotic being developed to treat hospitalized patients when limited or no treatment options are available for complicated intra-abdominal infections (cIAI) (in combination with metronidazole) and complicated urinary tract infections (cUTI) (including acute pyelonephritis) caused by Gram-negative pathogens.

5 Dec 2014

Bayer's Amikacin Inhale and Ciprofloxacin DPI receive QIDP designation from FDA

The U.S. Food and Drug Administration has granted qualified infectious disease product (QIDP) designation to two Bayer investigational agents, Amikacin Inhale and Ciprofloxacin Dry Powder for Inhalation (DPI).

24 Nov 2014

Research breakthrough offers hope for patients with severe spinal cord injuries

Case Western Reserve researchers have developed a procedure that restores function to muscles involved in the control of breathing - even when they have been paralyzed for more than a year. The breakthrough offers hope that one day patients with severe spinal cord injuries will be able to breathe again without the assistance of a ventilator.

19 Nov 2014

Study: Critically ill newborns may be exposed to DEHP chemicals in medical products

Hospitalized premature infants are exposed to unsafe levels of a chemical found in numerous medical products used to treat them, raising questions about whether critically ill newborns may be adversely affected by equipment designed to help save their lives.

14 Nov 2014

Enhanced dental care reduces respiratory tract infection risk in ICU patients

New research shows vulnerable patients in the Intensive Care Unit (ICU) who received enhanced oral care from a dentist were at significantly less risk for developing a lower respiratory tract infection (LRTI), like ventilator-associated pneumonia, during their stay.

25 Oct 2014

HAMILTON-C1 provides optimal ventilation therapy for neonates

The high‐performance capabilities of the HAMILTON‐C1 with the new Neonatal option include lung protective strategies and adaptive ventilation modes to ensure that each baby receives treatment tailored to its specific needs. Requiring only a minimum of space, the HAMILTON‐C1 combines high reliability, ease of use and maximum mobility with optimal performance for your most fragile patients.

23 Oct 2014

FDA grants QIDP and Fast Track designation to Nabriva's lefamulin for treatment of CABP, ABSSSI

Nabriva Therapeutics AG, a biotechnology company focused on developing pleuromutilins, a new class of antibiotics for the treatment of serious infections caused by resistant Gram-positive and Gram-negative pathogens, announced today that the United States Food and Drug Administration has granted Qualified Infectious Disease Product (QIDP) as well as Fast Track status designation to Nabriva's lead product lefamulin, for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI).

8 Oct 2014